[
  {
    "ts": "2026-01-28T01:04:51+00:00",
    "headline": "Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?",
    "summary": "AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...",
    "url": "https://finance.yahoo.com/news/does-abbvies-bispecific-trial-win-010451665.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7d700956-a51b-34e1-bb55-cd73897ba4f0",
      "content": {
        "id": "7d700956-a51b-34e1-bb55-cd73897ba4f0",
        "contentType": "STORY",
        "title": "Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?",
        "description": "",
        "summary": "AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...",
        "pubDate": "2026-01-28T01:04:51Z",
        "displayTime": "2026-01-28T01:04:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-abbvies-bispecific-trial-win-010451665.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-abbvies-bispecific-trial-win-010451665.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GMAB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T11:31:21+00:00",
    "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
    "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
    "url": "https://ca.finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
      "content": {
        "id": "182cce54-e0bf-3278-9a11-aae0e4384c80",
        "contentType": "STORY",
        "title": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
        "description": "",
        "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
        "pubDate": "2026-01-28T11:31:21Z",
        "displayTime": "2026-01-28T11:31:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y8.BnBtGUxBECcC9nPAbmg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VSVI8paIUF0YaI3N8PMZkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/52057ecfde4fda762bc487353a0bae0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exclusive-novos-wegovy-ozempic-us-110653009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T13:00:00+00:00",
    "headline": "Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.",
    "url": "https://finance.yahoo.com/news/allergan-aesthetics-unveils-data-across-130000722.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "98547e4f-a08e-3175-826c-368ae32d9248",
      "content": {
        "id": "98547e4f-a08e-3175-826c-368ae32d9248",
        "contentType": "STORY",
        "title": "Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine",
        "description": "",
        "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.",
        "pubDate": "2026-01-28T13:00:00Z",
        "displayTime": "2026-01-28T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/86bf9f66f56a0f0cfa9a0cb442718211",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sZeQLP5pfig9rLegzcts5g--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/86bf9f66f56a0f0cfa9a0cb442718211.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4DWTywnWeB6MtBpxR1jATg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/86bf9f66f56a0f0cfa9a0cb442718211.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/allergan-aesthetics-unveils-data-across-130000722.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/allergan-aesthetics-unveils-data-across-130000722.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:48:09+00:00",
    "headline": "Some of Pharma's Biggest Brands Face a New Reality",
    "summary": "A government process quietly moves forward",
    "url": "https://finance.yahoo.com/news/pharmas-biggest-brands-face-reality-144809825.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "4fce182c-2cef-3796-bb3c-381e42965b9d",
      "content": {
        "id": "4fce182c-2cef-3796-bb3c-381e42965b9d",
        "contentType": "STORY",
        "title": "Some of Pharma's Biggest Brands Face a New Reality",
        "description": "",
        "summary": "A government process quietly moves forward",
        "pubDate": "2026-01-28T14:48:09Z",
        "displayTime": "2026-01-28T14:48:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-biggest-brands-face-reality-144809825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-biggest-brands-face-reality-144809825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T15:00:11+00:00",
    "headline": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/abbvie-abbv-reports-next-week-150011999.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1010aaf0-8f77-3c84-947f-df4a76f26adc",
      "content": {
        "id": "1010aaf0-8f77-3c84-947f-df4a76f26adc",
        "contentType": "STORY",
        "title": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
        "description": "",
        "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2026-01-28T15:00:11Z",
        "displayTime": "2026-01-28T15:00:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
          "originalWidth": 900,
          "originalHeight": 876,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7_MbG.UY.XzK7FHlqhSdQ--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 900,
              "height": 876,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9cdhr7KlQi2r1salrGcJQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-reports-next-week-150011999.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-reports-next-week-150011999.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T21:14:46+00:00",
    "headline": "Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains",
    "summary": "If you are wondering whether AbbVie’s current share price lines up with its underlying value, you are not alone. This article is built to help you size that up clearly. AbbVie’s stock recently closed at US$223.93, after a 4.6% gain over the last 7 days, set against a 2.6% decline over 30 days, a 2.3% decline year to date, and a 32.4% return over 1 year, 68.9% over 3 years, and 162.1% over 5 years. Recent moves in AbbVie’s share price sit alongside ongoing interest in large pharmaceutical...",
    "url": "https://finance.yahoo.com/news/abbvie-abbv-pricing-reflect-dcf-211446993.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1b19d165-2cc3-35d1-83d2-47d69b57f143",
      "content": {
        "id": "1b19d165-2cc3-35d1-83d2-47d69b57f143",
        "contentType": "STORY",
        "title": "Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains",
        "description": "",
        "summary": "If you are wondering whether AbbVie’s current share price lines up with its underlying value, you are not alone. This article is built to help you size that up clearly. AbbVie’s stock recently closed at US$223.93, after a 4.6% gain over the last 7 days, set against a 2.6% decline over 30 days, a 2.3% decline year to date, and a 32.4% return over 1 year, 68.9% over 3 years, and 162.1% over 5 years. Recent moves in AbbVie’s share price sit alongside ongoing interest in large pharmaceutical...",
        "pubDate": "2026-01-28T21:14:46Z",
        "displayTime": "2026-01-28T21:14:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-pricing-reflect-dcf-211446993.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-pricing-reflect-dcf-211446993.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]